Clinical Trials · NCT03942653
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Manish Patel
- Enrollment
- 20
- Start date
- May 2019
- Locations
- 7 sites, United States
- Primary endpoint
- Objective Response Rate